4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by Barclays PLC

Barclays PLC lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 141.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 114,848 shares of the company’s stock after buying an additional 67,202 shares during the quarter. Barclays PLC owned about 0.25% of 4D Molecular Therapeutics worth $1,241,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp grew its position in 4D Molecular Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after acquiring an additional 37,232 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in 4D Molecular Therapeutics by 238.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after purchasing an additional 1,087,147 shares in the last quarter. Novo Holdings A S increased its position in 4D Molecular Therapeutics by 7.1% during the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after buying an additional 100,000 shares during the last quarter. Redmile Group LLC raised its holdings in 4D Molecular Therapeutics by 17.6% during the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after buying an additional 188,655 shares in the last quarter. Finally, Braidwell LP lifted its position in shares of 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after buying an additional 855,990 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on FDMT shares. Bank of America lowered their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday. Royal Bank of Canada decreased their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.56.

4D Molecular Therapeutics Stock Down 13.8 %

FDMT stock opened at $4.76 on Tuesday. 4D Molecular Therapeutics, Inc. has a twelve month low of $4.68 and a twelve month high of $36.25. The company has a market cap of $220.05 million, a PE ratio of -1.67 and a beta of 2.81. The business’s 50-day simple moving average is $6.94 and its 200 day simple moving average is $11.88.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.